Characterization of the Candidate Reference Material of Timothy Pollen Allergen Extract in Terms of Protein Profile and Specific Allergenic Components

Medicinal products based on pollen allergen extracts are widely used for diagnosis and therapy of pollinosis. According to the  requirements of the State Pharmacopoeia of the Russian Federation,  13th ed., the allergenic potency of such products is assessed against certified reference materials whose biological activity was confirmed in vivo in subjects sensitized to particular tested allergens. The finished dosage form of a candidate In-House Reference Material (IHRM) of timothy pollen allergen extract and the corresponding  allergen pollen extract (intermediate) were characterized in terms of  protein profile and allergenic composition using SDS-PAGE, gel- filtration HPLC, and western blotting. The test samples were  compared to finished pharmaceutical products (FPP) and pollen  allergen extracts produced at different dates and made from pollen  harvested at different dates, as well as to the WHO International  Standard (IS) of Timothy Pollen Extract (NIBSC code: 82/520). SDS- PAGE and gelfiltration HPLC showed that the candidate IHRM protein  profile was comparable in terms of major protein fractions to those  of all the FPP batches and pollen allergen extracts produced at  different dates. HPLC confirmed the comparability of the protein  profiles of the candidate IHRM and the IS (NIBSC code: 82/520), but showed minor  variations in the ratio of the main protein fractions.  Western blotting confirmed the presence of the main allergenic components with relative molecular masses ranging from 50 to 60  kDa and from 27 to 35 kDa. The composition of specific allergenic  components of timothy pollen allergen products manufactured by  JSC «SIC «Microgen» was identical with that of the WHO IS of  Timothy Pollen Extract in terms of the main protein and allergenic  components. 

1. D’Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, et al. Allergenic Pollen and Pollen Allergy in Europe. Allergy 2007;62(9):976–90. DOI: 10.1111/j.1398-9995.2007.01393.x

2. Gjesing B, Jäger L, Marsh DG, Løwenstein H. The International Collaborative Study Establishing the First International Standard for Timothy (Phleum pratense) Grass Pollen Allergenic Extract. J Allergy Clin Immunol. 1985;75(2):258–67.

3. Невская ЛВ, Радунская СФ, Лавренчик ЕИ, Мовсесянц АА, Капитанова ВК, Короткова МЮ. Применение иммуноанализа для решения актуальных проблем стандартизации препаратов аллергенов. БИОпрепараты. Профилактика, диагностика, лечение 2015;(3):17–20. [Nevskaya LV, Radunskaya SF, Lavrenchik EI, Movsesyants AA, Kapitanova VK, Korotkova MYu. Immunoassay for the Purpose of Solving Current Issues Associated with Standardization of Allergen Preparations. BIOpreparations. Prevention, Diagnosis, Treatment 2015;(3):17–20 (in Russ.)] DOI: 10.30895/2221-996X-2015-3-17-20

4. Общая фармакопейная статья 1.7.1.0001.15 Аллергены. Государственная фармакопея Российской Федерации. XIII изд. Т. 2, М.; 2015. [General Monograph 1.7.1.0001.15 Allergens. The State Pharmacopoeia of Russian Federation 13th ed. V. 2. Moscow; 2015 (in Russ.)] Available from: http://www.femb.ru/feml

5. Общая фармакопейная статья 1.2.1.0023.15 Электрофорез в полиакриламидном геле. Государственная фармакопея Российской Федерации. XIII изд. Т. 1, М.; 2015. [General Monograph 1.2.1.0023.15 SDS-PAGE. The State Pharmacopoeia of Russian Federation 13th ed. V. 1. Moscow; 2015 (in Russ.)] Available from: http://www.femb.ru/feml

6. Общая фармакопейная статья 1.7.2.0022.15 Определение подлинности и чистоты иммунобиологических лекарственных препаратов методом вестерн-блот. Государственная фармакопея Российской Федерации. XIII изд. Т. 2, М.; 2015. [General Monograph 1.7.2.0022.15 Characterization and Purity Determination of Biotherapeutics by Immunoblotting. The State Pharmacopoeia of Russian Federation 13th ed. V. 2. Moscow; 2015 (in Russ.)] Available from: http://www.femb.ru/feml

7. Общая фармакопейная статья 1.2.1.2.0001.15 Хроматография. Государственная фармакопея Российской Федерации. XIII изд. Т. 1, М.; 2015. [General Monograph 1.2.1.2.0001.15 Chromatography. The State Pharmacopoeia of Russian Federation 13th ed. V. 1. Moscow; 2015 (in Russ.)] Available from: http://www.femb.ru/feml

8. Общая фармакопейная статья 1.2.1.2.0005.15 Высокоэффективная жидкостная хроматография. Государственная фармакопея Российской Федерации. XIII изд. Т. 1, М.; 2015. [General Monograph 1.2.1.2.0005.15 High- Performance Liquid Chromatography. The State Pharmacopoeia of Russian Federation 13th ed. V. 1. Moscow; 2015 (in Russ.)] Available from: http://www.femb.ru/feml

9. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of Commercial Timothy Grass Pollen Extracts. Clin Exp Allergy 2008;38(8):1400–8. DOI: 10.1111/j.1365-2222.2008.03031.x

10. Matthiesen F, Løwenstein H. Group V Allergens in Grass Pollens. I. Purification and Characterization of the Group V Allergen from Phleum pratense Pollen, Phl p V. Clin Exp Allergy 1991;21(3):297–307.

11. Suck R, Petersen A, Hagen S, Cromwell O, Becker WM, Fiebig H. Complementary DNA Cloning and Expression of a Newly Recognized High Molecular Mass Allergen Phl p 13 from Timothy Grass Pollen (Phleum pratense). Clin Exp Allergy 2000;30(3):324–32.

12. Suck R, Hagen S, Cromwell O, Fiebig H. The High Molecular Mass Allergen Fraction of Timothy Grass Pollen (Phleum pratense) between 50–60 kDa is Comprised of Two Major Allergens: Phl p 4 and Phl p 13. Clin Exp Allergy. 2000;30(10):1395–402.

13. Sekerkova A, Polackova M, Striz I. Detection of Phl p 1, Phl p 5, Phl p 7 and Phl p 12 Specific IgE Antibodies in the Sera of Children and Adult Patients Allergic to Phleum Pollen. Allergol Int. 2012;61(2):339–46. DOI: 10.2332/allergolint.11-OA-0372

14. Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, Deviller P, et al. Profilins Constitute a Novel Family of Functional Plant Pan-allergens. J Exp Med. 1992;175(2):377–85.